广西医学2025，Vol.47Issue(3)：434-446,13.DOI:10.11675/j.issn.0253-4304.2025.03.16
比伐卢定治疗PCI术后无复流/慢血流有效性和安全性的Meta分析
Effectiveness and safety of bivalirudin for the treatment of no-reflow/slow-flow after PCI:a Meta-analysis
摘要
Abstract
Objective To systematically evaluate the effectiveness and safety of bivalirudin for the treatment of no-reflow/slow-flow after percutaneous coronary intervention(PCI).Methods Relevant literature of randomized controlled trials related to bivalirudin for the treatment of no-reflow/slow-flow after PCI was retrieved from databases such as PubMed,The Cochrane Library,Embase,Web of Science,China Biomedical Literature Service System,Wanfang Data Knowledge Service Platform,and China National Knowledge Infrastructure.After literature screening,data extraction,and quality assessment,Meta-analysis was performed by using the RevMan 5.4 and Stata 18 softwares.Results A total of 21 literature was included.The Meta-analysis results revealed that compared with the control group,the experimental group exhibited decreased incidence rate of thrombolysis in myocardial infarction(TIMI)flow grade≤2,corrected TIMI frame count,and incidence rate of TIMI myocardial perfusion grade≤2,whereas elevated proportion of electrocardiogram ST-segment resolution>70%,left ventricular ejection fraction at 7 days,1 month,and 3 months after PCI,and reduced major adverse cardiovascular events at 1 and 3 months after surgery(P<0.05).However,no statistically significant difference was observed in myocardial blush grade after PCI between the two groups(P>0.05).Conclusion Bivalirudin is effective for treating no-reflow/slow-flow after PCI,ameliorating myocardial reperfusion,and reducing the occurrence of major adverse cardiac events.关键词
比伐卢定/经皮冠状动脉介入治疗/无复流/慢血流/系统评价Key words
Bivalirudin/Percutaneous coronary intervention/No-reflow/Slow-flow/Systematic review分类
临床医学引用本文复制引用
吴青芸,李秋艳,苏强..比伐卢定治疗PCI术后无复流/慢血流有效性和安全性的Meta分析[J].广西医学,2025,47(3):434-446,13.基金项目
国家自然科学基金(81960079) （81960079）
广西自然科学基金项目(2020GXNSFFA297002) （2020GXNSFFA297002）
